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Abstract 
Background/Objectives: The detection of cancer-specific DNA in peripheral blood, known as a liquid 
biopsy, has been reported recently. Most such studies have used plasma as a sample; however, whether or 
not serum can be used as effectively is unclear. We attempted to clarify suitable samples for detecting KRAS 
mutations in circulating DNA in the blood of pancreatic cancer patients using droplet digital polymerase 
chain reaction (PCR). 
Methods: DNA was extracted from the tissue, plasma, and serum of 40 pancreatic cancer patients. The 
presence of KRAS mutations G12D, G12V, and G12R was analyzed by droplet digital PCR. 
Results: The amount of DNA isolated from the serum was much higher than that from plasma (1.0- to 42.0-
fold). At least 1 KRAS mutation was observed in 93% of cancer tissues, whereas we detected the mutations 
in only 48% of the serum and plasma DNA samples. The G12D mutation was the most prevalent of the 
three mutations, followed by the G12V mutation. The presence of the G12D KRAS mutation in the plasma, 
serum, or tissue did not correlate to the overall survival; however, the prognosis of the patients with a KRAS 
mutation at G12V in the plasma or serum was significantly poorer than that of the patients without the 
mutation (P < 0.01).  
Conclusions: Serum and plasma were found to be good materials for detecting cancer-specific DNA in the 
peripheral blood and the presence of KRAS mutations in blood-derived DNA may be used as a prognostic 
biomarker for patients with pancreatic cancer. 
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Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is associated with particularly poor outcomes. It is the eighth 
leading cause of cancer death in males and ninth among females worldwide [1]. During the progression 
from normal ductal epithelium to PDAC, multiple genetic alterations occur sequentially, such as mutations 
in KRAS, p16, p53, DPC4, and BRCA2 [2]. The mutations in KRAS occur at the pancreatic intraepithelial 
neoplasm (PanIN) stage, which is the most common precursor to invasive pancreatic adenocarcinoma [2, 
3]. The frequency of mutations in KRAS is very high in pancreatic cancer (75%-90%) [3-6], so KRAS 
mutations are expected to be useful biomarkers for early detection and/or as prognostic factors. 
Until recently, resected or biopsied tissue samples were needed to analyze the presence of mutations 
in KRAS. However, there are some disadvantages in the examination of tissue samples. First, it is invasive 
to obtain such samples from patients, and retrieving samples multiple times during treatment is difficult, as 
the repetition of biopsies simply increases the risk of complications. Second, we might miss crucial 
mutations occurring in only a small portion of the tissue, as there might be molecular heterogeneities in the 
tumor. To overcome these issues, a noninvasive method of assessing the total tumor characteristics—liquid 
biopsy—is under development. Cell-free circulating tumor DNA (ctDNA) theoretically comes from cancer 
cells, at rapidly growing sites in the tumor where cancer cells divide and collapse frequently; they are 
therefore representative of the genome at the poorest differentiation site in the tumor. Recently, the 
development of highly sensitive techniques, such as the digital polymerase chain reaction (PCR), beads, 
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emulsions, amplification, magnetics (BEAMing) or amplification refractory mutation systems (ARMs), 
have enabled the detection of cancer-specific DNA in the blood [7-10]. Generally, plasma has been used as 
the material for detecting ctDNA; very few techniques have used serum as a source because the serum 
contains genomic DNA released from white blood cells during the clotting process, which can interfere 
with the detection of ctDNA [11-14]. We recently examined the ctDNA in serum samples using droplet 
digital PCR and found that KRAS mutations could be detected at a relatively high rate (62.5%) in the serum 
of the patients with advanced pancreatic cancer [15]. However, whether plasma is superior or inferior to 
serum for the detection of ctDNA in this highly sensitive system is unclear.  
In this study, we compared the detection rates of KRAS mutations in ctDNA samples extracted from 
the serum and plasma of patients with pancreatic cancer and tried to determine the best samples for a liquid 
biopsy with digital droplet PCR. 
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Methods 
Characteristics of the Patients 
We selected patients with histologically diagnosed pancreatic cancer who were admitted to our institute 
between September 2013 and February 2016. Written informed consent for this study was obtained from 
all patients prior to their enrollment. Forty patients were enrolled in this study. Ten healthy individuals with 
no prior history of any cancers were recruited as controls. This study was approved by the institutional 
review board of Okayama University Hospital and was conducted in accordance with the Declaration of 
Helsinki. 
 
DNA extraction 
Tissue samples were collected from all pancreatic cancer patients by surgical resection or endoscopic 
ultrasound fine needle aspiration (EUS-FNA). DNA was extracted from 16 surgically resected formalin-
fixed, paraffin-embedded (FFPE) specimens using a QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, 
CA, USA), and from 24 samples obtained by EUS-FNA using a QIAamp DNA Mini Kit (Qiagen). Paired 
plasma and serum samples were also collected from all patients, with isolation performed within 3 h after 
blood sampling. Fifty microliters of circulating cell-free DNA was extracted from 1 mL each of paired 
plasma and serum using a QIAamp Circulating Nucleic Acid Kit (Qiagen) in accordance with the 
manufacturer’s instructions. DNA eluent was frozen at -30 °C until analyzed with droplet digital PCR. DNA 
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from paired plasma and serum samples of healthy individuals was also extracted by the same way. All 
obtained DNAs were quantified using a Qubit fluorometer (Thermo Fisher Scientific, Waltham, MA, USA 
[please describe the company location]). 
 
Digital droplet PCR 
We used a QX200 droplet digital PCR system (Bio-Rad Laboratories, Hercules, CA, USA) to analyze the 
presence of mutations and wild-type status in KRAS, as described previously [15]. We used three types of 
probes for KRAS to analyze the mutations G12D, G12V, and G12R (Bio-Rad Laboratories), as these are 
the three major KRAS mutations in pancreatic cancer [16, 17]. Five microliters of DNA from tissue, plasma, 
and serum was added to 10 μL of Droplet PCR Supermix (Bio-Rad Laboratories), 2 μL of primer/probe 
mixture and 5 μL of sterile DNase-and RNase-free water. A total 22 μL of mixture was added to 70 μL of 
Droplet generator oil (Bio-Rad Laboratories) in order to generate droplets. The emulsion was thermal 
cycled, starting with enzyme activation of 10 minutes at 95 °C, followed by 40 cycles of 30 seconds at 
94 °C and 1 minute at 60 °C. The cycling then finished with 10 minutes at 98 °C for enzyme deactivation. 
When the cycling was complete, the fluorescence signal of each droplet was measured. 
 
Data analysis 
The data of the fluorescence signals were analyzed with the Quanta software program, version 1.4.0 (Bio-
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Rad Laboratories), in accordance with the manufacturer’s instructions, to determine the number of droplets 
that were positive for wild-type KRAS and/or KRAS mutations. In this study, we set the cut-off values at 
2000 for the x-axis (mutation) and 2000 for the y-axis (wild-type). In addition to these cut-off values, we 
set the detection rate at >0.0222%. The detection rate was estimated with a Poisson distribution. 
 
Statistical analyses 
The baseline characteristics were summarized as medians and ranges. The overall survival was measured 
from the day of diagnosis to the date of death or the last follow-up date. The overall survival curves were 
calculated using the Kaplan-Meier method, and the log-rank test was used to compare the overall survival 
curves. All significance tests were two-sided, and differences with a p-value less than 0.05 were considered 
significant. All statistical analyses were performed using the JMP software program, ver. 11.0 (SAS Institute 
Japan Ltd., Tokyo, Japan). 
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Results 
Characteristics of the Patients 
The median age was 71 years (range 49-92 years), and 26 patients (65%) were male. Median size of primary 
tumor was 30 mm (range 14-69 mm). The number of patients in stage I, II, III, and IV was 2 (5%), 21 
(52%), 6 (15%), and 11 (28%), respectively. The median follow-up period was 7.8 months (range 0.3-30.2 
months). 
 
DNA concentrations in serum and plasma  
We analyzed the amount of DNA in the paired plasma and serum samples of healthy individuals and of 
pancreatic cancer patients (Figure 1). The median plasma DNA concentrations in pancreatic cancer patients 
and healthy individuals were 17.9 and 10.7 ng/mL, respectively (P <0.01). The DNA concentration in the 
plasma of stage III/IV pancreatic cancer patient tended to be higher than in stage I/II patients (22.6 and 15 
ng/mL, respectively), but the difference was not significant (P = 0.27). The median serum DNA 
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concentrations in pancreatic cancer patients and healthy individuals were 129 and 110 ng/mL (P = 0.73), 
respectively. The concentrations in the serum were much higher than those in plasma, by 7.2- and 10.3-fold, 
respectively. However, as with plasma, no significant differences in the concentrations were observed 
between the pancreatic cancer patients at stage I/II and those at stage III/IV. 
 
Determination of cut-off level for digital droplet PCR  
We analyzed the KRAS mutations in DNA samples extracted from 10 paired plasma and serum samples of 
healthy individuals. We detected the KRAS mutation G12D in 1 of the serum samples, as 1 mutation-type 
droplet in 3807 wild-type droplets. The frequency of the mutation droplet estimated with Poisson 
distribution was 0.0222%. We therefore judged this mutation-type droplet to be a false positive and defined 
a frequency over 0.0222% as the threshold of true positive.  
 
KRAS mutations in pancreatic cancer samples 
We compared the frequencies of KRAS mutations at G12D, G12V, and G12R in tissue, plasma, and serum 
samples (Table 2). The G12D mutation was the most prevalent mutation detected in pancreatic cancer tissue 
(73%), followed by G12V (43%) and G12R (23%). In total, 37 patients (93%) had at least 1 mutation. The 
order of the mutation rates in the plasma and serum was the same as that observed in the tissue samples; 
however, the detection rates in the blood samples (both plasma and serum) were lower than those in the 
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tissue samples.  
The mutation rates detected in the serum and plasma DNA were quite similar. The rate of the G12D 
mutation in plasma DNA and that in serum DNA were 38% and 40%, and those of the G12V mutation were 
13% and 10%, respectively. We did not detect the KRAS mutation at G12R in either plasma or serum DNA.  
The detection rates of the KRAS mutations at any of G12D, G12V, and G12R were the same for 
both blood sources (48%). In addition, no marked difference in the detection rate was observed between 
stage I/II and stage III/IV patients (Table 3). 
 
Overall survival rate and KRAS mutations 
In the follow-up period, 12 patients (30%) died of pancreatic cancer. The overall survival curves classified 
by KRAS mutation in tissue, plasma, and serum are shown in Figures 2 and 3. None of the KRAS mutations 
in tissue were related to the overall survival. However, while the KRAS mutation at G12D in plasma and 
serum was not related to the overall survival, the patients with the G12V mutation detected in serum or 
plasma showed a significantly shorter survival than those without the mutation (p < 0.01 and p < 0.01, 
respectively). All patients with the G12V mutation in serum or plasma were Stage III/IV, which was the 
only difference of the characteristics of the patients between the groups (Table 4a and 4b). In addition, all 
four patients with the G12V mutation in serum overlapped with those with the same mutation in plasma. 
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Discussion 
We analyzed the feasibility of plasma DNA and serum DNA as the samples of detecting KRAS mutations 
in patients with pancreatic cancer. The median amount of serum DNA was 7.2 times higher than that of 
plasma. The DNA concentration in the plasma of pancreatic cancer patients was significantly higher than 
that of healthy individuals, although we did not observe any marked difference in the serum DNA 
concentration. Among the three KRAS mutations, the frequency of the G12D mutation was the highest in 
tissue, plasma, and serum (73%, 38%, and 40%, respectively). Although the frequency was low in blood 
samples, no marked difference was observed between the plasma and serum. In terms of a prognostic factor, 
the mutation of KRAS at G12V both in the serum and plasma samples was strongly correlated to a poor 
overall survival, whereas that in tissue did not affect the overall survival. Because we did not observe any 
marked difference between the plasma and serum DNA regarding the detection rates of KRAS mutations, 
either can be used as a sample for a liquid biopsy. 
Several studies have been reported that the DNA in serum was 4- to 24-fold that in plasma [12-14, 
18]. In our study, the amount of DNA in serum was 7.2 times higher than that in the paired plasma samples, 
which concurred well with previous findings. This is mainly the result of the clotting process while isolating 
serum. When blood clots, the cells in the blood collapse, and their DNA flows out into the serum. 
Conventional methods like RT-PCR or an RFLP analysis are affected by the amount of non-mutated normal 
DNA derived from blood cells, which subsequently reduce their sensitivity for the detection of cancer-
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specific mutations. In this study, we clearly showed that droplet digital PCR was able to overcome this 
interference and demonstrated the usefulness of serum for detecting ctDNA.  
We previously reported that KRAS mutations in ctDNA are a better biomarker than those in tissue 
in terms of predicting the overall survival [15]. We were able to reproduce this advantage when using 
ctDNA in the present study. The KRAS mutation G12V in serum or plasma was a good marker for a poor 
prognosis. However, the major mutation detected in ctDNA, mutation G12D, did not have any obvious 
correlation with the prognosis. This mutation may instead be useful as a biomarker reflecting the therapeutic 
effect if monitored during therapy, as about 40% of patients with pancreatic cancer are positive for this 
mutation in ctDNA.  
In our first report, we focused on the detection rate of KRAS mutations in serum by examining 
patients with relatively advanced pancreatic cancer. In contrast, half of the patients were suffering from 
less-advanced cancer (stage I/II) in the present study; we were therefore able to evaluate the differences in 
the DNA concentrations and mutation detection rates across clinical stages. Although, there were no 
significant differences in the serum and plasma DNA concentrations between stages I/II and III/IV, the 
plasma DNA concentration in the advanced-stage patients was slightly higher than in less-advanced-stage 
patients, which concurred with the previous findings [19]. In contrast, the detection rates of the KRAS 
mutations were almost the same between the stage I/II and stage III/IV patients. These results indicated that 
we could detect genetic alterations by examining blood samples, even in patients with early-stage pancreatic 
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cancer. The sensitivity for detecting a rare mutation was approximately 0.01%, which was sufficient to 
detect a KRAS mutation in blood samples with innumerable normal DNA [7]. No marked differences in 
the detection rate were observed between serum and plasma samples, meaning that both are appropriate 
sample sources for this KRAS mutation analysis, as far as we determined. 
Several limitations associated with the present study warrant mention. First, the sensitivity of a liquid 
biopsy is lower than that using tissue and is not sufficient for screening pancreatic cancer in a clinical setting. 
This is likely due to the low amount of ctDNA in the blood compared to the tumor-derived DNA in tissue 
samples. Increasing the sample volume might help improve the sensitivity. Second, this is a retrospective 
study, and the number of patients was small. Although we were able to reproduce the relationship between 
the serum KRAS G12V mutation and the overall survival with a new cohort in this study, a prospective 
study is required to verify the relationship conclusively. 
In conclusion, the detection rates of KRAS mutations in serum and plasma DNA were almost equal, 
regardless of the differences in the amount of extracted DNA, and both serum and plasma DNA can be used 
as prognostic biomarkers for pancreatic cancer. 
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Table1. Patient Characteristics 
  
N = 40 
Age (years) 
 
71 (49-92) 
Sex (male, %) 
 
26 (65%) 
Diabetes mellitus 
 
16 (41%) 
Size (mm) 
 
30 (14-69) 
Stage of disease 
(UICC) 
Ⅰ 2 (5%) 
Ⅱ 22 (55%) 
Ⅲ 7 (18%) 
Ⅳ 9 (22%) 
CEA (ng/mL) 
 
4.4 (0.2-1379) 
CA19-9 (IU/mL) 
 
112 (0.6-91973) 
SPAN-1 (IU/mL) 
 
77 (10-62000) 
DUPAN2 (IU/mL) 
 
292 (25-16000) 
Initial therapy BSC 3 (8%) 
 
Chemo therapy 15 (37%) 
 
Surgery 22 (55%) 
                                                          Median (range) 
20 
 
CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, SPAN-1: s-pancreas-1 antigen, 
DUPAN-2: duke pancreatic monoclonal antigen type 2, BSC: best supportive care 
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Table2. Frequency of KRAS mutations in tissue, serum, and plasma 
 Tissue Plasma Serum P-value 
G12D 29 (73%) 15 (38%) 16 (40%) 0.82 
G12V 17 (43%) 5 (13%) 4 (10%) 0.72 
G12R 9 (23%) 0 (0%) 0 (0%) - 
KRAS 
(G12D or G12V or G12R) 
37 (93%) 19 (48%) 19 (48%) 1.00 
The P-value indicates the proportion between plasma and serum. 
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Table3. Comparison of the DNA concentrations and mutation frequency in stage I/II or III/IV 
  Stage I/II (n = 24) Stage III/IV (n = 16) P-value 
Mutation rate 
Tissue 21 (88%) 16 (100%) 0.26 
Plasma 9 (38%) 10 (63%) 0.20 
Serum 9 (38%) 10 (63%) 0.20 
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Table 4a. Characteristics of the patients with or without G12V mutation in serum  
 
  With G12V mutation in serum 
(n = 4) 
Without G12V mutation in 
serum (n = 36) 
P-value 
Age (years) 74.5 (59-81) 70.5 (49-92) 0.73  
Sex (male, %) 2 (50%) 24 (67%) 0.60  
Diabetes mellitus 2 (50%) 14 (39%) 1.00  
Size (mm) 33 (20-40) 30 (14-69) 0.91  
Stage (III/IV, %) 4 (100%) 12 (33%) 0.02  
CEA (ng/mL) 64.0 (1.36-115.8) 4.3 (0.2-1379) 0.11  
CA19-9 (IU/mL) 15.6 (0.6-117) 157.2 (0.6-91973) 0.09  
SPAN-1 (IU/mL) 69 (18.4-181.8) 77.4 (10-62000) 0.79  
DUPAN2 (IU/mL) 2227 (25-16000) 292 (25-16000) 0.66  
Median (range) 
Abbreviations were the same as indicated in Table 1.  
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Table 4b. Characteristics of the patients with or without G12V mutation in plasma 
  
With G12V mutation in plasma 
(n =5) 
Without G12V mutation in 
plasma (n = 35) 
P-value 
Age (years) 81 (59-91) 70 (49-92) 0.29  
Sex (male, %) 2 (40%) 24 (69%) 0.32  
Diabetes mellitus 2 (40%) 14 (40%) 1.00  
Size (mm) 28 (20-40) 30 (14-69) 0.77  
Stage (III/IV, %) 4 (100%) 12 (33%) 0.02  
CEA (ng/mL) 41.7 (1.36-115.8) 4.2 (0.2-1379) 0.10  
CA19-9 (IU/mL) 30.2 (0.6-336.1) 155.6 (0.6-91973) 0.19  
SPAN-1 (IU/mL) 78.6 (18.4-181.8) 10 (10-62000) 0.82  
DUPAN2 (IU/mL) 338 (25-16000) 270.5 (25-16000) 0.63  
Median (range) 
Abbreviations were the same as indicated in Table 1. 
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Figure legends 
Figure 1. Comparison of the DNA concentrations between plasma and serum samples 
 The median serum DNA concentrations in pancreatic cancer patients and healthy individuals were much 
higher than those in plasma, by 7.2- and 10.3-fold, respectively. The concentration of plasma DNA in 
pancreatic cancer patients was higher than that in healthy volunteers, whereas no marked difference was 
observed in serum samples. The horizontal bars in the boxes and numbers beside them indicate the median 
values.  
 
Figure 2. The survival of the patients with pancreatic cancer with different KRAS mutations in cancer 
tissue 
None of the three KRAS mutations in tissue (G12D, G12V, G12R) were related to the overall survival. 
G12D in tissue (a), G12V in tissue (b) and G12R in tissue (c). 
 
Figure 3. The survival of the patients with pancreatic cancer with or without KRAS mutations in 
serum or plasma DNA 
The patients with the G12V mutation in serum or plasma showed a significantly shorter survival than the 
patients without this mutation (p <0.01 and p <0.01, respectively). G12D in plasma (a), G12V in plasma 
(b), G12D in serum (c) and G12V in serum (d). 
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